This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work against omicron.
Academic rigor, journalistic flair
Articles on Remdesivir
Displaying 1 - 20 of 30 articles
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.
Medications to treat COVID-19 are in no way a substitute for the vaccine. But under the right circumstances, some show great promise for helping patients.
A lack of medicines manufacturing capability in Australia puts us at significant risk.
This treatment would work by targeting the SARS-CoV-2 virus itself and stopping it in its tracks. The evidence we have so far is promising, but it’s still very early days.
The UK government has created an antivirus taskforce to develop new drugs against coronavirus.
A year after it became clear that COVID-19 was becoming a pandemic, there is still no cure, but doctors have several innovative treatments. Some are keeping patients out of the hospital entirely.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Monoclonal antibodies are synthetic molecules manufactured in the lab. But do we need them if a vaccine is on its way?
Death rates for hospitalized COVID-19 patients fell from 25.6% in March to 7.6% in August, according to a new study on three hospitals in New York. A study in the UK found similar results.
There’s still a lot of uncertainty, but the picture is gradually getting clearer – here’s what we know so far.
The long-awaited study of the coronavirus drug, remdesivir, has just been published.
The president and first lady Melania Trump have both tested positive for the coronavirus. Here’s what the physicians and scientists know about the best treatments for the disease it causes.
The global pandemic has fueled illicit online sales of COVID-19 commodities, some of which are dangerous or illegal. Researchers are assessing the size and reach of this underground market.
Most people diagnosed with COVID-19 can manage their illness at home. But some patients deteriorate after about 5 days. Fortunately, Australian doctors have up-to-the-minute treatment guidelines.
The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they’re available to all.
The US has bought up most of the world’s supply of remdesivir. This type of treatment nationalism is nothing new, though.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Professor of Medicine, University of Virginia
-
Professor of Philosophy, Binghamton University, State University of New York
-
Professor and Director of the Stoneygate Centre for Excellence in Empathic Healthcare, University of Leicester
-
Associate Lecturer Pharmacy Practice, University of Sydney
-
Advisor to the Editor in Chief, Cochrane Australia/Cochrane Collaboration (UK), researcher & Cochrane author, Monash University
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Lecturer of Law, Global Health, Keele University
-
Senior Lecturer in Pharmacology, Keele University
-
Associate Director of Microbiology, University of California, San Diego
-
Clinical Research Fellow in Viral Immunology and Veterinary Surgeon, University of Cambridge
-
Professor of Cancer Virology, University of Leeds
-
Executive Director, National COVID-19 Clinical Evidence Taskforce, and Professor, School of Public Health and Preventive Medicine, Monash University
